Inhibikase (IKT) director receives 155,000 stock options at $1.91 strike price
Rhea-AI Filing Summary
Inhibikase Therapeutics, Inc. director David Canner received a grant of stock options covering 155,000 shares of common stock. The options have an exercise price of $1.91 per share and expire on June 26, 2036.
The options vest on the earlier of June 26, 2027 or the day before the next annual stockholder meeting, contingent on his continued board service. Following this award, Canner holds 155,000 derivative securities directly.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Canner David
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 155,000 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 155,000 shares (Direct)
Footnotes (1)
- F1. The options will vest on the earlier of June 26, 2027 or the day prior to the next annual meeting of stockholders, subject to the director's continued service through such date.
Key Figures
Option grant size: 155,000 options
Exercise price: $1.91 per share
Expiration date: June 26, 2036
+3 more
6 metrics
Option grant size
155,000 options
Stock Option (Right to Buy) granted to director
Exercise price
$1.91 per share
Conversion/exercise price of stock options
Expiration date
June 26, 2036
Option grant expiration
Underlying shares
155,000 shares
Common Stock underlying granted options
Post-grant derivative holdings
155,000 options
Total derivative securities following transaction
Vesting date trigger
June 26, 2027
Earlier of this date or day before next annual meeting
Key Terms
Stock Option (Right to Buy), exercise price, vest, annual meeting of stockholders, +1 more
5 terms
Stock Option (Right to Buy) financial
"security_title: "Stock Option (Right to Buy)""
exercise price financial
"conversion_or_exercise_price: "1.9100""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vest financial
"The options will vest on the earlier of June 26, 2027"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
annual meeting of stockholders financial
"or the day prior to the next annual meeting of stockholders"
derivative securities financial
"derivativeTransactionCount: 1"
Financial contracts whose value is tied to the price or performance of another asset, such as a stock, bond, commodity, index, or currency; examples include options, futures and swaps. They matter to investors because they let you protect against price swings, bet on future moves or gain larger exposure with less upfront cash—like using a lever or insurance policy on an investment—so they can amplify gains and losses and help manage portfolio risk.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transaction did Inhibikase Therapeutics (IKT) report for David Canner?
Inhibikase Therapeutics reported that director David Canner received a grant of 155,000 stock options. These options give him the right to buy common shares at a fixed exercise price, reflecting equity-based director compensation rather than an open-market share purchase or sale.
What is the exercise price and size of David Canner’s new Inhibikase (IKT) stock options?
David Canner was granted 155,000 stock options with an exercise price of $1.91 per share. This means he can buy up to 155,000 Inhibikase common shares at $1.91 if the options vest and are exercised before expiration.
When do David Canner’s Inhibikase (IKT) stock options vest?
The options will vest on the earlier of June 26, 2027 or the day before Inhibikase’s next annual stockholder meeting. Vesting is conditioned on Canner’s continued service as a director through that date, aligning the award with ongoing board tenure.
What is the expiration date of David Canner’s newly granted Inhibikase (IKT) options?
David Canner’s stock options expire on June 26, 2036. He must wait for the options to vest, then exercise them before this expiration date to purchase Inhibikase common shares at the fixed $1.91 strike price specified in the grant.
How many Inhibikase (IKT) derivative securities does David Canner hold after this option grant?
After the award, David Canner holds 155,000 derivative securities, all from this stock option grant. These represent rights to acquire Inhibikase common shares, not currently owned shares, and are subject to vesting and later exercise at $1.91 per share.